Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 37 | 2023 | 233 | 7.330 |
Why?
|
| Gonorrhea | 28 | 2023 | 180 | 6.440 |
Why?
|
| Antibodies, Bacterial | 13 | 2023 | 184 | 2.780 |
Why?
|
| Bacterial Vaccines | 9 | 2023 | 87 | 2.710 |
Why?
|
| Lipopolysaccharides | 18 | 2022 | 632 | 2.700 |
Why?
|
| Cytidine Monophosphate | 3 | 2020 | 12 | 1.900 |
Why?
|
| Complement System Proteins | 10 | 2022 | 115 | 1.670 |
Why?
|
| Sialic Acids | 6 | 2020 | 39 | 1.550 |
Why?
|
| Epitopes | 7 | 2021 | 294 | 1.320 |
Why?
|
| Complement Factor H | 13 | 2022 | 132 | 1.130 |
Why?
|
| Antigens, Bacterial | 8 | 2023 | 198 | 1.060 |
Why?
|
| Mice, Inbred BALB C | 12 | 2021 | 876 | 1.050 |
Why?
|
| N-Acetylneuraminic Acid | 5 | 2020 | 50 | 1.010 |
Why?
|
| Neuraminic Acids | 2 | 2020 | 5 | 0.880 |
Why?
|
| Cytidine Monophosphate N-Acetylneuraminic Acid | 3 | 2020 | 10 | 0.870 |
Why?
|
| Complement Activation | 3 | 2021 | 49 | 0.800 |
Why?
|
| Immunoglobulin G | 9 | 2022 | 450 | 0.770 |
Why?
|
| Oligosaccharides | 5 | 2020 | 60 | 0.750 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 173 | 0.720 |
Why?
|
| Peptides | 3 | 2019 | 549 | 0.720 |
Why?
|
| Sialyltransferases | 4 | 2020 | 22 | 0.720 |
Why?
|
| Cathelicidins | 1 | 2020 | 5 | 0.720 |
Why?
|
| Bacterial Outer Membrane Proteins | 4 | 2019 | 121 | 0.700 |
Why?
|
| Bacterial Proteins | 3 | 2023 | 734 | 0.700 |
Why?
|
| Drug Resistance, Multiple | 2 | 2020 | 33 | 0.680 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 53 | 0.660 |
Why?
|
| Mice | 21 | 2023 | 10317 | 0.660 |
Why?
|
| Complement C4b-Binding Protein | 6 | 2019 | 34 | 0.640 |
Why?
|
| Serum Bactericidal Antibody Assay | 1 | 2019 | 7 | 0.630 |
Why?
|
| Animals | 29 | 2023 | 19739 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 853 | 0.590 |
Why?
|
| Histocompatibility Antigens | 2 | 2019 | 107 | 0.540 |
Why?
|
| Immunoglobulin Fc Fragments | 5 | 2020 | 44 | 0.510 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 42 | 0.510 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2013 | 43 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 59 | 0.430 |
Why?
|
| Vagina | 4 | 2023 | 81 | 0.420 |
Why?
|
| Female | 23 | 2023 | 31224 | 0.400 |
Why?
|
| Immunization, Passive | 3 | 2021 | 99 | 0.400 |
Why?
|
| Disease Models, Animal | 11 | 2023 | 2074 | 0.390 |
Why?
|
| Properdin | 1 | 2012 | 13 | 0.390 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2022 | 496 | 0.390 |
Why?
|
| Complement Pathway, Alternative | 1 | 2012 | 23 | 0.390 |
Why?
|
| Complement Pathway, Classical | 3 | 2012 | 22 | 0.370 |
Why?
|
| Porins | 8 | 2019 | 71 | 0.340 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 1224 | 0.290 |
Why?
|
| Humans | 34 | 2022 | 60081 | 0.290 |
Why?
|
| Immunotherapy | 3 | 2020 | 235 | 0.270 |
Why?
|
| Chlamydia Infections | 2 | 2022 | 76 | 0.260 |
Why?
|
| Flow Cytometry | 5 | 2016 | 638 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 3215 | 0.210 |
Why?
|
| Neisseria meningitidis | 4 | 2011 | 81 | 0.210 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2002 | 3 | 0.200 |
Why?
|
| alpha-Macroglobulins | 1 | 2002 | 4 | 0.200 |
Why?
|
| Coinfection | 1 | 2022 | 44 | 0.200 |
Why?
|
| Blood Bactericidal Activity | 4 | 2011 | 67 | 0.200 |
Why?
|
| Mannans | 1 | 2002 | 19 | 0.200 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 70 | 0.200 |
Why?
|
| Cell Division | 1 | 2023 | 442 | 0.200 |
Why?
|
| Lectins | 1 | 2002 | 38 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 448 | 0.190 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 23 | 0.180 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2020 | 51 | 0.170 |
Why?
|
| Protein Binding | 8 | 2017 | 1571 | 0.170 |
Why?
|
| Heptoses | 2 | 2018 | 9 | 0.170 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 114 | 0.170 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 1965 | 0.160 |
Why?
|
| Mass Spectrometry | 3 | 2018 | 288 | 0.160 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 41 | 0.160 |
Why?
|
| Lactose | 1 | 2018 | 12 | 0.150 |
Why?
|
| Amino Acid Sequence | 6 | 2011 | 1572 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 225 | 0.150 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1387 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2002 | 703 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2015 | 592 | 0.140 |
Why?
|
| Virulence Factors | 1 | 2017 | 82 | 0.130 |
Why?
|
| Neuraminidase | 1 | 2016 | 49 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 20 | 0.130 |
Why?
|
| Complement C4b | 2 | 2007 | 11 | 0.130 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1995 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 98 | 0.120 |
Why?
|
| Drug Design | 1 | 2016 | 143 | 0.120 |
Why?
|
| Genitalia, Female | 1 | 2015 | 18 | 0.120 |
Why?
|
| Bacterial Load | 1 | 2015 | 29 | 0.120 |
Why?
|
| Microbiota | 1 | 2016 | 104 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2016 | 137 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 735 | 0.110 |
Why?
|
| Bacteria | 1 | 2016 | 277 | 0.110 |
Why?
|
| Virulence | 2 | 2012 | 187 | 0.110 |
Why?
|
| Male | 9 | 2022 | 27949 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2013 | 174 | 0.100 |
Why?
|
| Adult | 5 | 2018 | 15972 | 0.100 |
Why?
|
| Antibody Specificity | 1 | 2012 | 100 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2011 | 175 | 0.090 |
Why?
|
| Macrophage-1 Antigen | 1 | 2010 | 30 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 129 | 0.090 |
Why?
|
| Serum | 2 | 2007 | 30 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 214 | 0.090 |
Why?
|
| Complement Inactivator Proteins | 1 | 2008 | 9 | 0.070 |
Why?
|
| Complement C3b | 1 | 2007 | 18 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 356 | 0.070 |
Why?
|
| Tularemia | 1 | 2007 | 17 | 0.070 |
Why?
|
| Hybridomas | 1 | 2007 | 65 | 0.070 |
Why?
|
| Galactosyltransferases | 2 | 2007 | 16 | 0.070 |
Why?
|
| Mutation | 4 | 2011 | 2466 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2011 | 477 | 0.070 |
Why?
|
| Chlamydia trachomatis | 2 | 2022 | 56 | 0.070 |
Why?
|
| Immune Sera | 1 | 2005 | 34 | 0.060 |
Why?
|
| Defensins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Urethritis | 1 | 2005 | 9 | 0.060 |
Why?
|
| Base Sequence | 2 | 2005 | 1301 | 0.060 |
Why?
|
| DNA Probes | 1 | 2005 | 35 | 0.060 |
Why?
|
| Microbial Viability | 2 | 2018 | 55 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 99 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 290 | 0.060 |
Why?
|
| Ethanolamines | 1 | 2003 | 17 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2005 | 376 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2005 | 367 | 0.050 |
Why?
|
| Neutrophils | 1 | 2005 | 352 | 0.050 |
Why?
|
| Species Specificity | 3 | 2008 | 334 | 0.050 |
Why?
|
| Fimbriae Proteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Serum Bactericidal Test | 1 | 2002 | 3 | 0.050 |
Why?
|
| Collectins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 49 | 0.050 |
Why?
|
| Opsonin Proteins | 1 | 2002 | 31 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2002 | 28 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 114 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 133 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 2 | 2016 | 238 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 667 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 142 | 0.040 |
Why?
|
| China | 1 | 2018 | 140 | 0.040 |
Why?
|
| Pan troglodytes | 2 | 2008 | 36 | 0.030 |
Why?
|
| Neisseria | 1 | 2016 | 5 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 34 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2008 | 246 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 737 | 0.030 |
Why?
|
| Survival | 1 | 2011 | 12 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2011 | 34 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2011 | 136 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 101 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 146 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 190 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 375 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5264 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 806 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 673 | 0.020 |
Why?
|
| Papio | 1 | 2008 | 13 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 28 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 153 | 0.020 |
Why?
|
| Francisella tularensis | 1 | 2007 | 23 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 26 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2007 | 122 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2007 | 56 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 148 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 195 | 0.020 |
Why?
|
| Immunization | 1 | 2007 | 130 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2008 | 353 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 417 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 13 | 0.020 |
Why?
|
| Serotyping | 1 | 2005 | 50 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2005 | 189 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2005 | 291 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2005 | 80 | 0.010 |
Why?
|
| Urethra | 1 | 2005 | 60 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 396 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 184 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 52 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 144 | 0.010 |
Why?
|
| Poly G | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 112 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 379 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2002 | 257 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 808 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 16540 | 0.010 |
Why?
|